PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.75%
Revenue growth of 3.75% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
10.29%
Gross profit growth of 10.29% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
11.03%
EBIT growth of 11.03% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
42.26%
Operating income growth of 42.26% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
26.24%
Positive net income growth while Medical - Pharmaceuticals median is negative. Peter Lynch would view this as a notable competitive advantage.
26.24%
EPS growth of 26.24% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
26.24%
Diluted EPS growth of 26.24% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
0.00%
Share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.03%. Joel Greenblatt would applaud significant buybacks if they are value-accretive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.65%
10Y revenue/share CAGR 75-90% of Medical - Pharmaceuticals median of 10.21%. John Neff would seek operational improvements to catch up with peers.
-2.00%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 10.02%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-30.84%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-100.00%
Negative 5Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
No Data
No Data available this quarter, please select a different quarter.
51.37%
Net income/share CAGR 1.25-1.5x Medical - Pharmaceuticals median. Mohnish Pabrai would confirm that management’s capital allocation strategy drives the outperformance.
22.70%
Net income/share CAGR of 22.70% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
-13.67%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
62.70%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 6.78% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
33.26%
5Y equity/share CAGR 1.25-1.5x Medical - Pharmaceuticals median. Mohnish Pabrai might see disciplined retention of earnings behind outperformance.
-10.59%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 13.12%. Seth Klarman sees a short-term weakness if peers still expand net worth.
-45.83%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
41.30%
5Y dividend/share CAGR of 41.30% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
-26.14%
Dividend reductions while Medical - Pharmaceuticals median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
25094.44%
AR growth of 25094.44% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-1.93%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
3.97%
Asset growth of 3.97% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
5.74%
BV/share growth of 5.74% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
54.19%
Debt growth of 54.19% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-41.59%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.